Published • loading... • Updated
ISOThrive Final Phase 2 Results for MHS-1031 Announced at ACG 2026 Demonstrate Statistically Significant and Clinically Meaningful Improvement in Heartburn Frequency and Severity in NERD PPI-Partial Responders
The investigational glycan therapeutic met all primary and secondary endpoints and significantly reduced regurgitation scores, researchers said.
Summary by Rutland Herald
2 Articles
2 Articles
Rutland HeraldReposted by 
Weatherford Democrat
Weatherford DemocratISOThrive Final Phase 2 Results for MHS-1031 Announced at ACG 2026 Demonstrate Statistically Significant and Clinically Meaningful Improvement in Heartburn Frequency and Severity in NERD PPI-Partial Responders
ACG Presidential Poster Award winner for high quality, novel, unique, or interesting research
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
